In the latest move by a country to crack down on anti-competitive behavior by drug makers, Ukrainian regulators fined Sanofi (SNY) approximately $2.6 million for purportedly working with two distributors to restrict competition of dozens of medicines several years ago.
In a decision issued on Tuesday, the Antimonopoly Committee explained that, during 2010 and 2011, the drug maker provided unspecified “conditions and discounts” to the distributors — BadMM and Optimum-Farm — to market Sanofi medicines for which lower-cost generic competition existed.
About the Author Reprints
